Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease.

Alimentary pharmacology & therapeutics·2026
Same author

Inflammatory bowel disease must be a policy priority after the 2025 United Nations declaration on non-communicable diseases and mental health.

Journal of Crohn's & colitis·2026
Same author

Exploring role of therapeutic plasma exchange for hepatitis A-related acute liver failure: An Indian multi-center cohort study.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.

Journal of Crohn's & colitis·2026
Same author

Exclusive enteral nutrition for induction of remission in Crohn's disease in adults: A systematic review and meta-analysis of randomized trials and real-world studies.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis.

Scientific reports·2026

Related Experiment Video

Updated: Jul 3, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.

Omesh Goyal1, Manjeet Kumar Goyal2, Bhupinder Singh3

  • 1Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Alimentary Pharmacology & Therapeutics
|July 1, 2026
PubMed
Summary

Elobixibat significantly improved symptoms and quality of life in functional constipation patients compared to prucalopride. This study suggests ileal bile acid transporter inhibition is a valuable second-line treatment for FC.

Related Experiment Videos

Last Updated: Jul 3, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Functional constipation (FC) treatment choices are often empirical due to limited direct comparisons.
  • Elobixibat (ileal bile acid transporter inhibitor) and prucalopride (5-HT4 receptor agonist) offer distinct mechanisms for FC.
  • This study directly compared elobixibat and prucalopride in FC patients refractory to first-line therapy.

Purpose of the Study:

  • To directly compare the efficacy of elobixibat versus prucalopride in patients with functional constipation.
  • To evaluate sustained complete spontaneous bowel movement (CSBM) response as the primary endpoint.
  • To assess secondary outcomes including stool consistency, associated symptoms, and quality of life.

Main Methods:

  • A multicentre, prospective, pragmatic study with blinded outcome assessment was conducted.
  • Adults meeting Rome IV criteria for FC and refractory to first-line treatment were enrolled.
  • Participants received either elobixibat or prucalopride for 8 weeks, with a primary endpoint of sustained CSBM response.

Main Results:

  • Elobixibat demonstrated a significantly higher sustained CSBM response (55.6%) compared to prucalopride (33.9%; p=0.024).
  • Both treatments improved CSBM frequency and stool consistency, but elobixibat showed greater improvements in straining, abdominal discomfort, bloating, and quality of life.
  • Both elobixibat and prucalopride were well tolerated by patients.

Conclusions:

  • Elobixibat provides superior overall symptomatic relief and quality-of-life improvement in FC patients compared to prucalopride.
  • The dual mechanism of action of elobixibat may contribute to its enhanced efficacy.
  • Ileal bile acid transporter (IBAT) inhibition should be considered as a second-line treatment option for functional constipation.